Back to discover
Disease

Lymphoma, T-Cell, Cutaneous

Late-stage therapeutic developmentEmerging research
MeSHLymphoma, T-Cell, Cutaneous
2
Publications
13
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials with recent milestones.
Clinical Milestones2View
Other updates 2
Activity timeline2

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Bexaroteneapproved

Approval — Targretin capsules are indicated for the treatment of skin manifestations of advanced sta… (2001)

Clinical trials

9 sponsors · 0 new · 0 completed in the last 12 months (net -2)

The current development programme across all trial phases.

Clinical programme
13
All trials
0
Active
3
Late-stage
6
Completed
Recently completed

A Phase 1b Study of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-cell Lymphoma, CD30-positive Peripheral T-cell Lymphoma, or CD30-positive Hodgkin Lymphoma

Phase 1 · Completed · Peter MacCallum Cancer Centre, Australia

A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas

Phase 1 · Completed · Washington University School of Medicine

A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Phase 2 · Completed · Janssen Research & Development, LLC

A Phase I/II Open Label, Multi-Center Study For The Evaluation Of Pf-3512676 (CPG 7909) In Patients With Stage Ib To Iva Cutaneous T-Cell Lymphoma

Phase 1/2 · Completed · Pfizer

A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25

Phase 4 · Completed · Eisai Inc.

Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status

Phase 4 · Completed · Eisai Inc.

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2001emaApproval — Bexarotene· Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20052024
Major themes5
  • Lymphoma, T-Cell, Cutaneous1
  • Mycosis Fungoides1
  • Sezary Syndrome1
  • Skin Neoplasms1
  • World Health Organization1
Leading journals2
  • Blood1
  • Cells1
Leading researchers8
  • Agostinelli C1
  • Berti E1
  • Burg G1
  • Cerroni L1
  • Chimenti S1
  • Diaz-Perez JL1
  • Duncan LM1
  • Grange F1
Affiliations (unnormalised)4
  • Institute of Dermatology1
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna1
  • Leiden University Center1
  • University of Bologna1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.

Identifiers
MeSHLymphoma, T-Cell, Cutaneous
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.